6 Case, Special Counsel Says ICON CEO Steve Cutler says trial activity has been “impacted by cautious spending from biopharma customers in both the biotech and large pharma businesses.” ...

"ICON Public Limited Company (NASDAQ:ICLR): The stock pulled back on news that biotechnology funding has dropped, albeit from very strong growth levels. We continue to believe the company is a ...